加巴喷丁治疗维持性血液透析患者皮肤瘙痒症的临床研究  

Clinical study of Gabapentin in the treatment of uremic pruritus in hemodialysis patients

作　　者：庞家亮[1] 魏崇一[1] 石建华[1] 

机构地区：[1]河南省新乡市第一人民医院血液净化中心,453000

出　　处：《中国实用医药》2011年第21期7-8,共2页China Practical Medicine

摘　　要：目的评价加巴喷丁治疗维持性血液透析(MHD)患者皮肤瘙痒症的疗效及安全性。方法采用随机对照研究,选择顽固性皮肤瘙痒的MHD患者,随机分为试验组20例和对照组20例。试验组患者每周3次透析后晚间服加巴喷丁100～300mg,对照组服用安慰剂。4周后根据视觉模拟评分(VAS)进行疗效评价,同时观察不良反应。结果治疗组得分平均下降(6.0±2.6)分,安慰剂组平均下降(1.3±1.9)分。两组VAS得分下降程度有明显差异(P<0.01)。没有患者因药物副作用而中断治疗。结论加巴喷丁治疗顽固性尿毒症皮肤瘙痒症是安全和有效的。Objective To evaluate the safety and efficacy of Gabapentin in treatment of refractory uremic pruritus in maintenance hemodialysis（MHD）patients.Methods A randomized controlled trial was performed.Forty MHD patients with severe pruritus were randomly divided into treatment group（Gabapentin 100-300 rag at dialysis day before sleep）and the placebo group.The efficacy was assessed by visual analogue score after 4-week treatment,and the side effect was also observed to assess the safety.Results The mean decrease in pruritus score in gabapentin and placebo groups was（6.0±2.3）and（1.3±1.9）scores,respectively（P0.001）.None of the patients was forced to drop out of the study due to side effects of the treatment.Conclusion Gabapentin is safe and effective for refractory uremic pruritus.

关 键 词：加巴喷丁 尿毒症瘙痒症 血液透析 

分 类 号：R692.5[医药卫生—泌尿科学]